Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 74 | 2023 | 1220 | 7.580 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 37 | 2023 | 1667 | 3.270 |
Why?
|
Radiotherapy Dosage | 45 | 2023 | 2911 | 1.850 |
Why?
|
Genital Neoplasms, Female | 8 | 2023 | 534 | 1.460 |
Why?
|
Catheters | 11 | 2023 | 424 | 1.290 |
Why?
|
Radiometry | 16 | 2020 | 812 | 1.170 |
Why?
|
Prostatic Neoplasms | 40 | 2021 | 11094 | 1.100 |
Why?
|
Rectum | 14 | 2017 | 896 | 0.930 |
Why?
|
Iodine Radioisotopes | 10 | 2012 | 1030 | 0.890 |
Why?
|
Radiation Dosage | 8 | 2017 | 1952 | 0.710 |
Why?
|
Gold | 5 | 2014 | 479 | 0.570 |
Why?
|
Organs at Risk | 4 | 2017 | 365 | 0.570 |
Why?
|
Film Dosimetry | 3 | 2020 | 30 | 0.560 |
Why?
|
Prostate | 12 | 2021 | 1757 | 0.520 |
Why?
|
Radiotherapy, Conformal | 7 | 2011 | 545 | 0.510 |
Why?
|
Needles | 2 | 2022 | 459 | 0.490 |
Why?
|
Magnetic Resonance Imaging | 32 | 2023 | 36562 | 0.490 |
Why?
|
Software Validation | 1 | 2014 | 59 | 0.470 |
Why?
|
Metal Nanoparticles | 3 | 2014 | 398 | 0.470 |
Why?
|
Uterine Cervical Neoplasms | 9 | 2021 | 2039 | 0.460 |
Why?
|
Cone-Beam Computed Tomography | 3 | 2015 | 447 | 0.450 |
Why?
|
Electromagnetic Phenomena | 1 | 2014 | 159 | 0.430 |
Why?
|
Urinary Bladder | 8 | 2017 | 1155 | 0.420 |
Why?
|
Phantoms, Imaging | 10 | 2022 | 2473 | 0.390 |
Why?
|
Uncertainty | 2 | 2014 | 764 | 0.370 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2010 | 348 | 0.360 |
Why?
|
Drug Implants | 3 | 2016 | 230 | 0.350 |
Why?
|
Artifacts | 7 | 2015 | 1896 | 0.350 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2017 | 877 | 0.340 |
Why?
|
Radiation Injuries | 6 | 2010 | 1192 | 0.330 |
Why?
|
Colon, Sigmoid | 5 | 2017 | 124 | 0.320 |
Why?
|
Quality Control | 4 | 2019 | 834 | 0.320 |
Why?
|
Catheterization | 2 | 2012 | 1427 | 0.310 |
Why?
|
Imaging, Three-Dimensional | 7 | 2015 | 4047 | 0.310 |
Why?
|
Monte Carlo Method | 4 | 2009 | 1249 | 0.300 |
Why?
|
Strontium Radioisotopes | 2 | 2004 | 18 | 0.280 |
Why?
|
Radiation Protection | 3 | 2010 | 424 | 0.280 |
Why?
|
Models, Theoretical | 4 | 2017 | 3562 | 0.270 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2014 | 8925 | 0.270 |
Why?
|
Radiotherapy, Computer-Assisted | 4 | 2014 | 90 | 0.260 |
Why?
|
Tomography, X-Ray Computed | 16 | 2021 | 20706 | 0.260 |
Why?
|
Quality Assurance, Health Care | 3 | 2017 | 2170 | 0.250 |
Why?
|
Algorithms | 11 | 2021 | 14071 | 0.250 |
Why?
|
Prostheses and Implants | 3 | 2013 | 1274 | 0.230 |
Why?
|
Magnetic Resonance Imaging, Interventional | 3 | 2017 | 193 | 0.230 |
Why?
|
Iridium Radioisotopes | 1 | 2004 | 26 | 0.230 |
Why?
|
Models, Biological | 5 | 2014 | 9458 | 0.230 |
Why?
|
Pattern Recognition, Automated | 3 | 2014 | 978 | 0.210 |
Why?
|
Radiotherapy | 3 | 2011 | 1497 | 0.200 |
Why?
|
Fiducial Markers | 2 | 2014 | 134 | 0.190 |
Why?
|
Uterine Neoplasms | 3 | 2017 | 1424 | 0.180 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 794 | 0.180 |
Why?
|
Catheters, Indwelling | 2 | 2014 | 436 | 0.180 |
Why?
|
Feasibility Studies | 7 | 2021 | 5302 | 0.180 |
Why?
|
Ultrasonography, Interventional | 2 | 2014 | 1520 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2012 | 3357 | 0.180 |
Why?
|
Coronary Restenosis | 1 | 2003 | 396 | 0.170 |
Why?
|
Graft Occlusion, Vascular | 1 | 2004 | 538 | 0.170 |
Why?
|
Radiography, Interventional | 1 | 2008 | 1127 | 0.170 |
Why?
|
Breast | 2 | 2008 | 1971 | 0.170 |
Why?
|
Humans | 91 | 2023 | 766432 | 0.170 |
Why?
|
Prostate-Specific Antigen | 7 | 2019 | 2463 | 0.170 |
Why?
|
Electrical Equipment and Supplies | 1 | 2019 | 28 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2019 | 9401 | 0.160 |
Why?
|
Vaginal Neoplasms | 2 | 2012 | 105 | 0.150 |
Why?
|
Reproducibility of Results | 12 | 2015 | 20129 | 0.150 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1150 | 0.150 |
Why?
|
Calibration | 4 | 2019 | 814 | 0.140 |
Why?
|
Adenocarcinoma | 6 | 2016 | 6361 | 0.140 |
Why?
|
Sensitivity and Specificity | 9 | 2014 | 14643 | 0.140 |
Why?
|
Immobilization | 2 | 2012 | 227 | 0.140 |
Why?
|
Nanoparticles | 3 | 2016 | 1966 | 0.130 |
Why?
|
Research Report | 1 | 2019 | 367 | 0.130 |
Why?
|
Eye Neoplasms | 1 | 1998 | 305 | 0.130 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2016 | 66 | 0.130 |
Why?
|
Biopsy, Needle | 2 | 2001 | 1615 | 0.130 |
Why?
|
Equipment Design | 4 | 2017 | 3481 | 0.130 |
Why?
|
Retinoblastoma | 1 | 1998 | 319 | 0.130 |
Why?
|
Numerical Analysis, Computer-Assisted | 2 | 2006 | 120 | 0.120 |
Why?
|
Male | 44 | 2021 | 363975 | 0.120 |
Why?
|
Phthalazines | 1 | 2017 | 397 | 0.120 |
Why?
|
Nanocapsules | 1 | 2015 | 92 | 0.110 |
Why?
|
Silicon Dioxide | 1 | 2015 | 217 | 0.110 |
Why?
|
Fluorescence | 1 | 2016 | 751 | 0.110 |
Why?
|
Technology, Radiologic | 2 | 2007 | 158 | 0.110 |
Why?
|
Electrons | 1 | 2014 | 264 | 0.110 |
Why?
|
Chitosan | 2 | 2010 | 138 | 0.100 |
Why?
|
Urinary Retention | 2 | 2005 | 100 | 0.100 |
Why?
|
Lung Neoplasms | 3 | 2021 | 13486 | 0.100 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2210 | 0.100 |
Why?
|
Surface Properties | 2 | 2012 | 1153 | 0.100 |
Why?
|
Software | 4 | 2021 | 4464 | 0.100 |
Why?
|
Intraoperative Period | 1 | 2012 | 511 | 0.090 |
Why?
|
Air | 1 | 2012 | 182 | 0.090 |
Why?
|
Retrospective Studies | 16 | 2021 | 81588 | 0.090 |
Why?
|
Taxoids | 1 | 2015 | 665 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2947 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1117 | 0.090 |
Why?
|
Skin Diseases | 1 | 2020 | 1083 | 0.090 |
Why?
|
Gamma Rays | 1 | 2012 | 324 | 0.090 |
Why?
|
Computer Simulation | 7 | 2014 | 6259 | 0.090 |
Why?
|
Piperazines | 2 | 2017 | 2546 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2012 | 1787 | 0.090 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2016 | 749 | 0.090 |
Why?
|
Female | 28 | 2023 | 396354 | 0.090 |
Why?
|
Risk Assessment | 4 | 2019 | 24272 | 0.080 |
Why?
|
Metals | 1 | 2014 | 711 | 0.080 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1227 | 0.080 |
Why?
|
Prospective Studies | 11 | 2021 | 54826 | 0.080 |
Why?
|
Water | 1 | 2015 | 1417 | 0.080 |
Why?
|
Carcinoid Tumor | 2 | 2009 | 225 | 0.080 |
Why?
|
Breast Neoplasms | 4 | 2010 | 21157 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 513 | 0.080 |
Why?
|
Polyglycolic Acid | 1 | 2010 | 406 | 0.080 |
Why?
|
Light | 1 | 2014 | 1358 | 0.080 |
Why?
|
Cisplatin | 1 | 2014 | 1656 | 0.080 |
Why?
|
Dental Restoration, Permanent | 1 | 2009 | 130 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2007 | 1126 | 0.080 |
Why?
|
X-Ray Film | 1 | 2008 | 31 | 0.070 |
Why?
|
Treatment Outcome | 13 | 2018 | 65202 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2016 | 4049 | 0.070 |
Why?
|
Robotics | 1 | 2014 | 806 | 0.070 |
Why?
|
Endometrial Neoplasms | 2 | 2008 | 1380 | 0.070 |
Why?
|
Vagina | 3 | 2010 | 849 | 0.070 |
Why?
|
Drug Approval | 1 | 2014 | 820 | 0.070 |
Why?
|
Societies, Medical | 1 | 2019 | 3953 | 0.070 |
Why?
|
Apoptosis | 1 | 2023 | 9507 | 0.070 |
Why?
|
Organ Size | 1 | 2012 | 2261 | 0.070 |
Why?
|
Urethra | 3 | 2008 | 406 | 0.070 |
Why?
|
Transistors, Electronic | 1 | 2007 | 23 | 0.070 |
Why?
|
Thoracic Neoplasms | 1 | 2009 | 269 | 0.070 |
Why?
|
HeLa Cells | 1 | 2012 | 3072 | 0.070 |
Why?
|
Rectal Diseases | 1 | 2007 | 141 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 1673 | 0.070 |
Why?
|
Skin Physiological Phenomena | 1 | 2007 | 193 | 0.060 |
Why?
|
Motion | 2 | 2006 | 782 | 0.060 |
Why?
|
Drug Carriers | 1 | 2010 | 702 | 0.060 |
Why?
|
Delayed-Action Preparations | 1 | 2009 | 966 | 0.060 |
Why?
|
Radiography | 3 | 2006 | 6967 | 0.060 |
Why?
|
Peer Review | 1 | 2008 | 218 | 0.060 |
Why?
|
Aged | 24 | 2019 | 171234 | 0.060 |
Why?
|
Survival Rate | 3 | 2019 | 12825 | 0.060 |
Why?
|
Movement | 1 | 2012 | 1468 | 0.060 |
Why?
|
Lactic Acid | 1 | 2010 | 1137 | 0.060 |
Why?
|
Computer Systems | 3 | 2003 | 467 | 0.060 |
Why?
|
Body Burden | 1 | 2005 | 156 | 0.060 |
Why?
|
Salvage Therapy | 2 | 2009 | 1274 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2012 | 2352 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5389 | 0.060 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2006 | 243 | 0.060 |
Why?
|
Carcinoma | 2 | 2007 | 2323 | 0.060 |
Why?
|
Finite Element Analysis | 1 | 2006 | 441 | 0.060 |
Why?
|
Mediastinal Neoplasms | 1 | 2006 | 403 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 1226 | 0.050 |
Why?
|
Beta Particles | 1 | 2003 | 52 | 0.050 |
Why?
|
Relative Biological Effectiveness | 1 | 2005 | 313 | 0.050 |
Why?
|
Middle Aged | 24 | 2019 | 223127 | 0.050 |
Why?
|
Medical Errors | 1 | 2011 | 1260 | 0.050 |
Why?
|
Ultrasonography | 2 | 2014 | 5988 | 0.050 |
Why?
|
Rotation | 2 | 2008 | 514 | 0.050 |
Why?
|
bcl-2-Associated X Protein | 1 | 2023 | 281 | 0.050 |
Why?
|
Watchful Waiting | 2 | 2018 | 492 | 0.050 |
Why?
|
Self Medication | 1 | 2002 | 115 | 0.050 |
Why?
|
Yttrium Radioisotopes | 1 | 2003 | 116 | 0.050 |
Why?
|
User-Computer Interface | 2 | 2017 | 1407 | 0.050 |
Why?
|
Niacin | 1 | 2002 | 116 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3849 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2018 | 39283 | 0.050 |
Why?
|
Biophysical Phenomena | 2 | 2001 | 317 | 0.050 |
Why?
|
Biophysics | 2 | 2001 | 375 | 0.050 |
Why?
|
Neoplasm Staging | 5 | 2018 | 11217 | 0.040 |
Why?
|
Aged, 80 and over | 7 | 2017 | 59538 | 0.040 |
Why?
|
Organ Specificity | 1 | 2005 | 1966 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8885 | 0.040 |
Why?
|
Prostatic Hyperplasia | 2 | 2000 | 514 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6508 | 0.040 |
Why?
|
Urination Disorders | 1 | 2000 | 236 | 0.040 |
Why?
|
Neoplasms | 4 | 2014 | 22343 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 790 | 0.040 |
Why?
|
Perineum | 1 | 2000 | 212 | 0.040 |
Why?
|
Cell Death | 1 | 2023 | 1676 | 0.040 |
Why?
|
Drug Interactions | 1 | 2002 | 1419 | 0.040 |
Why?
|
Coronary Stenosis | 1 | 2004 | 798 | 0.040 |
Why?
|
Kinetics | 2 | 2019 | 6285 | 0.040 |
Why?
|
Automation | 1 | 2020 | 586 | 0.040 |
Why?
|
Head and Neck Neoplasms | 2 | 2009 | 2928 | 0.030 |
Why?
|
Risk Factors | 6 | 2018 | 74828 | 0.030 |
Why?
|
Scattering, Radiation | 1 | 1998 | 483 | 0.030 |
Why?
|
Lens, Crystalline | 1 | 1998 | 387 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15820 | 0.030 |
Why?
|
Prostatectomy | 1 | 2003 | 1786 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12527 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10740 | 0.030 |
Why?
|
Image Enhancement | 3 | 2014 | 2856 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13639 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40116 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2017 | 475 | 0.030 |
Why?
|
Vascular Diseases | 1 | 2003 | 1161 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 859 | 0.030 |
Why?
|
Coronary Artery Bypass | 1 | 2004 | 2188 | 0.030 |
Why?
|
Mammaplasty | 1 | 2005 | 1268 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7426 | 0.030 |
Why?
|
Diffusion | 1 | 2016 | 808 | 0.030 |
Why?
|
Mammography | 1 | 2005 | 2430 | 0.030 |
Why?
|
Animals | 7 | 2023 | 168887 | 0.030 |
Why?
|
Adult | 8 | 2017 | 223253 | 0.030 |
Why?
|
Risk Management | 1 | 2017 | 558 | 0.030 |
Why?
|
Electromagnetic Fields | 1 | 2014 | 290 | 0.030 |
Why?
|
Computer Graphics | 1 | 2014 | 345 | 0.020 |
Why?
|
Nanostructures | 1 | 2017 | 549 | 0.020 |
Why?
|
Chickens | 1 | 2014 | 842 | 0.020 |
Why?
|
Particle Size | 1 | 2016 | 1634 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2021 | 3681 | 0.020 |
Why?
|
Boston | 2 | 2017 | 9333 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5981 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2006 | 2660 | 0.020 |
Why?
|
Nanomedicine | 1 | 2014 | 289 | 0.020 |
Why?
|
Prognosis | 3 | 2019 | 29922 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81863 | 0.020 |
Why?
|
Equipment Failure | 1 | 2013 | 584 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6845 | 0.020 |
Why?
|
Radiation Oncology | 1 | 2017 | 570 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2014 | 2275 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1900 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2017 | 1155 | 0.020 |
Why?
|
Fluoresceins | 1 | 2010 | 235 | 0.020 |
Why?
|
Drug Stability | 1 | 2010 | 289 | 0.020 |
Why?
|
Polymethyl Methacrylate | 1 | 2010 | 129 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3610 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5872 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 17082 | 0.020 |
Why?
|
Intraoperative Care | 2 | 2003 | 768 | 0.020 |
Why?
|
Drug Compounding | 1 | 2010 | 236 | 0.020 |
Why?
|
Dental Amalgam | 1 | 2009 | 64 | 0.020 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 391 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3605 | 0.020 |
Why?
|
Nanotechnology | 1 | 2014 | 702 | 0.020 |
Why?
|
Biopsy | 1 | 2000 | 6778 | 0.020 |
Why?
|
Dental Materials | 1 | 2009 | 113 | 0.020 |
Why?
|
Mastectomy | 2 | 2008 | 1861 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2011 | 428 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4888 | 0.020 |
Why?
|
Mediastinum | 1 | 2009 | 272 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2613 | 0.020 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
Retina | 1 | 1998 | 2656 | 0.020 |
Why?
|
Quality of Life | 1 | 2009 | 13472 | 0.020 |
Why?
|
X-Rays | 1 | 1987 | 309 | 0.020 |
Why?
|
Fecal Incontinence | 1 | 2009 | 246 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2653 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 437 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 873 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2920 | 0.020 |
Why?
|
Online Systems | 1 | 2006 | 181 | 0.020 |
Why?
|
Postoperative Care | 1 | 2012 | 1480 | 0.020 |
Why?
|
Leiomyosarcoma | 1 | 2009 | 426 | 0.020 |
Why?
|
Urinary Incontinence | 1 | 2009 | 490 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2007 | 829 | 0.010 |
Why?
|
Tongue Neoplasms | 1 | 2006 | 185 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 1012 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2228 | 0.010 |
Why?
|
Life Tables | 1 | 2003 | 367 | 0.010 |
Why?
|
Pelvis | 1 | 2008 | 737 | 0.010 |
Why?
|
Preoperative Care | 2 | 2002 | 2253 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 461 | 0.010 |
Why?
|
Precipitating Factors | 1 | 2002 | 51 | 0.010 |
Why?
|
Ejaculation | 1 | 2002 | 59 | 0.010 |
Why?
|
Proctitis | 1 | 2002 | 40 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1727 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 265 | 0.010 |
Why?
|
Prothrombin Time | 1 | 2002 | 117 | 0.010 |
Why?
|
Feedback | 1 | 2006 | 797 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2693 | 0.010 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 1097 | 0.010 |
Why?
|
Child, Preschool | 1 | 2023 | 42576 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9601 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23611 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2014 | 4306 | 0.010 |
Why?
|
Peritoneum | 1 | 2000 | 226 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 1204 | 0.010 |
Why?
|
Odds Ratio | 1 | 2011 | 9654 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3552 | 0.010 |
Why?
|
Sarcoma | 1 | 2009 | 1802 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18322 | 0.010 |
Why?
|
Antibiotic Prophylaxis | 1 | 2002 | 641 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2008 | 3466 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2002 | 903 | 0.010 |
Why?
|
Young Adult | 2 | 2016 | 59928 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13276 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11872 | 0.010 |
Why?
|
Heart | 1 | 2008 | 4421 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2003 | 3608 | 0.010 |
Why?
|
Child | 1 | 2023 | 80668 | 0.010 |
Why?
|
United States | 2 | 2014 | 72910 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 88898 | 0.010 |
Why?
|
Acute Disease | 1 | 2005 | 7240 | 0.010 |
Why?
|
Pilot Projects | 1 | 2006 | 8720 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5089 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 8042 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2003 | 2902 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6212 | 0.010 |
Why?
|
Regression Analysis | 1 | 2000 | 6327 | 0.010 |
Why?
|
Lung | 1 | 2008 | 10064 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2002 | 12979 | 0.000 |
Why?
|
Patient Selection | 1 | 1998 | 4248 | 0.000 |
Why?
|